Physician profile
Mark Meyer
NPI 1306836002
$1,591.96
in general payments reported to CMS, 2019-2025
29 companies · $13.50 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $230 · 2021: $446 · 2022: $466 · 2025: $13.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $224.62 | 2019-2025 | Evenity |
| Abbvie INC. | $147.85 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $144.68 | 2021-2022 | |
| Novo Nordisk INC | $126.84 | 2019-2022 | |
| Amarin Pharma, INC. | $113.08 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.75 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $88.90 | 2019-2022 | |
| Pfizer INC. | $74.06 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $53.20 | 2019-2022 | |
| Lilly USA, LLC | $52.13 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $50.85 | 2019-2022 | |
| Lundbeck LLC | $49.54 | 2022 | |
| Astellas Pharma US INC | $49.44 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $39.39 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $38.60 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $32.35 | 2021 | |
| Allergan, INC. | $30.54 | 2020 | |
| Sanofi-Aventis U.S. LLC | $25.98 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $19.63 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.60 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.91 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.89 | 2021 | |
| Glaxosmithkline, LLC. | $12.50 | 2019 | |
| Esperion Therapeutics, INC. | $12.34 | 2021 | |
| Circassia INC. | $12.14 | 2020 | |
| Jazz Pharmaceuticals INC. | $11.73 | 2021 | |
| Scilex Pharmaceuticals INC. | $11.44 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.04 | 2019 | |
| Sanofi Pasteur INC. | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.